Dr. Apolo on Managing Toxicities With Checkpoint Inhibitors in Bladder Cancer

Andrea B. Apolo, MD
Published: Friday, Dec 01, 2017

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing toxicities with checkpoint inhibitors in bladder cancer.

Apolo says that it is important for urologists to understand proper management of patients with bladder cancer who are undergoing therapy with checkpoint inhibitors.

Investigators are hoping to move checkpoint inhibitors to earlier states of disease, such as muscle-invasive and non-muscle invasive bladder cancer. Urologists will see these patients treated with these agents in their clinic.
 
Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing toxicities with checkpoint inhibitors in bladder cancer.

Apolo says that it is important for urologists to understand proper management of patients with bladder cancer who are undergoing therapy with checkpoint inhibitors.

Investigators are hoping to move checkpoint inhibitors to earlier states of disease, such as muscle-invasive and non-muscle invasive bladder cancer. Urologists will see these patients treated with these agents in their clinic.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x